Literature DB >> 16202848

The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension.

Albert W Dreisbach1, Shanker Japa, Aster Sigel, Melissa B Parenti, Arthur E Hess, Sengkeo L Srinouanprachanh, Allan E Rettie, Helen Kim, Federico M Farin, L Lee Hamm, Juan J L Lertora.   

Abstract

BACKGROUND: The cytochrome P450 (CYP) epoxygenase pathway produces arachidonic acid metabolites that are vasoactive, that affect renal sodium handling, and that have been proposed to play a mechanistic role in hypertension. Multiple single nucleotide polymorphisms (SNP) in CYP2C8, 2C9, 2J2 and soluble epoxide hydrolase (sEH) have been identified, many of which have altered functional activity in vitro. We performed a case-control study to determine the prevalence of epoxygenase-related SNP in African American individuals and to evaluate whether these SNP are associated with increased risk of hypertension.
METHODS: Normotensive African American individuals (N = 107) and African American patients with hypertension (N = 108) were recruited. DNA was extracted from a venous blood sample and genotyped for CYP2C8*2,*3, CYP2C9*2-*5,*8,*11, CYP2J2 *2-*7, L50L, R49S, V113M, N124S, sEH R287Q, and sEH 403Rins variant alleles by allelic discrimination using real-time polymerase chain reaction. Genotype and allele frequencies were calculated and associations with hypertension were estimated using unconditional logistic regression, adjusting for age and sex.
RESULTS: No association was found between any of the variant alleles and hypertension. We did find that only the CYP2C8*3and CYP2C9*2 alleles were in strong linkage disequilibrium in both the hypertensive and healthy African American groups, a finding that was reported previously in healthy individuals of white ethnicity.
CONCLUSIONS: These results suggest that these epoxygenase-related SNP are not associated with increased risk of hypertension in the African American population. There was significant linkage disequilibrium between CYP2C8*3 and CYP2C9*2 alleles that was not associated with hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16202848     DOI: 10.1016/j.amjhyper.2005.04.019

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  28 in total

Review 1.  Between candidate genes and whole genomes: time for alternative approaches in blood pressure genetics.

Authors:  Jacob Basson; Jeannette Simino; D C Rao
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

2.  Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.

Authors:  Paulo Arnaldo; Ricardo Estevão Thompson; Márcia Quinhones Lopes; Philip Noel Suffys; Adalberto Rezende Santos
Journal:  Malays J Med Sci       Date:  2013-07

3.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

Review 4.  Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.

Authors:  Fan Fan; Richard J Roman
Journal:  J Am Soc Nephrol       Date:  2017-07-12       Impact factor: 10.121

5.  Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure.

Authors:  Dong Sun; Azita J Cuevas; Katherine Gotlinger; Sung Hee Hwang; Bruce D Hammock; Michal L Schwartzman; An Huang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-02-21       Impact factor: 4.733

Review 6.  Epoxyeicosatrienoic acids, hypertension, and kidney injury.

Authors:  John D Imig
Journal:  Hypertension       Date:  2015-01-12       Impact factor: 10.190

Review 7.  Epoxyeicosanoids in hypertension.

Authors:  J D Imig
Journal:  Physiol Res       Date:  2019-09-02       Impact factor: 1.881

8.  PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.

Authors:  Dorit S Berlin; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-05       Impact factor: 2.089

Review 9.  Soluble epoxide hydrolase in atherosclerosis.

Authors:  Yi-Xin Jim Wang; Arzu Ulu; Le-Ning Zhang; Bruce Hammock
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

Review 10.  Soluble epoxide hydrolase: gene structure, expression and deletion.

Authors:  Todd R Harris; Bruce D Hammock
Journal:  Gene       Date:  2013-05-20       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.